• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Zydus Wellness Ltd.
    06 Jan 2023
    Split 10-year high
    515.64
    -1.64%
    Zydus Lifesciences launches generic anti-epilepsy drug in US market
    Zydus Lifesciences launches generic anti-epilepsy drug in US market
    Business Standard
    Zydus Lifesciences on Friday said it has launched generic epilepsy treatment medication in the US market. Zydus Pharmaceuticals (USA) Inc, a unit of the company, has launched Topiramate extended-release capsules in the American market. The company had earlier received final approval from the US Food and Drug Administration (USFDA) to market the product in strengths of USP 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a statement. Zydus is the first company to receive final approval and launch the medication in the above mentioned strengths, it added. Topiramate extended-release capsules are indicated for epilepsy: initial monotherapy in patients who are six years of age and older with partial onset or primary generalized tonic-clonic seizures. It is also indicated for prophylaxis of migraine in patients 12 years of age and older. As per IQVIA data, Topiramate extended-release capsule had annual sales of USD 488 million in the US.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 126 to 135 in Jun 2025 qtr.
    Zydus launches generic anti-epilepsy drug in US market
    Moneycontrol | 06 Jan 2023 1 more
    Today's Pick: Zydus Lifesciences (432.4): BUY
    Business Line | 06 Jan 2023
    logo
    Zydus Wellness Ltd.
    30 Dec 2022
    Split 10-year high
    515.64
    -1.64%
    Zydus Life gets final nod from USFDA for generic version of insomnia drug
    Zydus Life gets final nod from USFDA for generic version of insomnia drug
    Business Standard
    Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator to market its generic version of Triazolam tablets used on a short-term basis to treat insomnia. The approval granted by the US Food and Drug Administration (USFDA) is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the company said in a regulatory filing. The medicine is used on a short-term basis to treat insomnia -- difficulty falling asleep or staying asleep. It works by slowing activity in the brain to allow sleep. It will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, the company said. Triazolam tablets had annual sales of USD 11.7 million in the US, the company said, citing IQVIA MAT September 2022 data.
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. is trading above all available SMAs
    logo
    Zydus Wellness Ltd.
    29 Dec 2022
    Split 10-year high
    515.64
    -1.64%
    Zydus' Covid vax ZyCoV-D falls behind as the pace picks up for precautionary doses
    Business Line
    Against the order of 1 crore doses, Government procured only 1.5 lakh doses of India's first needle-less plasmid DNA vaccine
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has gained 32.34% in the last 3 Months
    logo
    Britannia Industries Ltd.
    28 Dec 2022
    6097.50
    -1.69%
    Buy Britannia Industries; target of Rs 5060: Sharekhan
    Buy Britannia Industries; target of Rs 5060: Sharekhan
    Moneycontrol
    Sharekhan is bullish on Britannia Industries has recommended buy rating on the stock with a target price of Rs 5060 in its research report dated December 27, 2022.
    Copy LinkShare onShare on Share on Share on
    Axis Direct upgraded Britannia Industries Ltd. to Buy with a price target of 6750.0 on 05 Sep, 2025.
    logo
    Zydus Wellness Ltd.
    21 Dec 2022
    Split 10-year high
    515.64
    -1.64%
    Nepal bans import of medicines from 16 Indian companies, including Patanjali's Divya Pharmacy, Zydus
    Nepal bans import of medicines from 16 Indian companies, including Patanjali's Divya Pharmacy, Zydus
    Business Today
    The move comes after the WHO issued an alert on Indian-made cough syrups, which were allegedly responsible for the deaths of children in Gambia.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 126 to 135 in Jun 2025 qtr.
    logo
    Nestle India Ltd.
    20 Dec 2022
    1204.30
    0.01%
    Nestle India may hike prices, to venture into small towns
    Business Line
    Nestle India has witnessed growth of value packs and premium products across the market
    Copy LinkShare onShare on Share on Share on
    Axis Direct increased Buy price target of Nestle India Ltd. to 1340.0 on 05 Sep, 2025.
    logo
    Nestle India Ltd.
    14 Dec 2022
    1204.30
    0.01%
    Nestle has bigger appetite for India; increasing presence in rurban markets
    Nestle has bigger appetite for India; increasing presence in rurban markets
    Business Standard
    The Swiss processed foods maker has significantly upped investments in its Indian subsidiary to expand its penetration in 'rurban' markets
    Copy LinkShare onShare on Share on Share on
    Nestle India Ltd. is trading above all available SMAs
    logo
    Zydus Wellness Ltd.
    10 Dec 2022
    Split 10-year high
    515.64
    -1.64%
    Zydus gets USFDA nod for two generic drugs
    Zydus gets USFDA nod for two generic drugs
    Business Today
    The company has also received final approval from the US Food and Drug Administration (USFDA) to market Pregabalin capsules in multiple strengths, the Ahmedabad-based drug maker said in a statement.
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has gained 32.34% in the last 3 Months
    Zydus gets USFDA nod for two generic drugs
    Moneycontrol | 10 Dec 2022
    logo
    Vadilal Industries Ltd.
    09 Dec 2022
    5601.00
    -1.84%
    Vadilal Ind soars 10% on board nod to buy 'Vadilal' brand from promoter co
    Vadilal Ind soars 10% on board nod to buy 'Vadilal' brand from promoter co
    Business Standard
    The company's board on Thursday approved the purchase of the "Vadilal" brand from its promoter group entity Vadilal International; the stock later pared half of its gains
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 33 to 48 in Jun 2025 qtr.
    logo
    Zydus Wellness Ltd.
    02 Dec 2022
    Split 10-year high
    515.64
    -1.64%
    Zydus gets final USFDA nod to market epilepsy and menopause drugs
    Zydus gets final USFDA nod to market epilepsy and menopause drugs
    livemint
    With a market valuation of 41,515.55 Cr, Zydus Lifesciences Ltd. is a large cap business that operates in the pharmaceutical industry.
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. is trading above all available SMAs
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • TechD Cybersecurity
    • Vms Tmt
    • Sampat Aluminium
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd